Cost minimization analysis of mainstay treatments in cutaneous lupus erythematous
- 4 November 2021
- journal article
- research article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (1) , e15190
Abstract
Background Cutaneous lupus erythematosus (CLE) can be treated with multiple oral immunosuppressants but cost analyses of these treatments are lacking. Objectives We aimed to assess the relative cost difference between various oral medications for CLE using a cost-minimization analysis. Methods Annual direct costs for ten oral medications used in CLE were calculated including costs of medications and patient monitoring, which include office visits, laboratory and radiological studies, and procedures. Medication costs were taken from the National Average Drug Acquisition Cost calculated by the Centers of Medicare and Medicaid Services or the Average Wholesale Price. Monitoring guidelines were obtained from expert consensus and FDA-approved recommendations. Results Methotrexate had the lowest total direct cost ($899.31), followed by hydroxychloroquine ($1,007.38), mycophenolate mofetil ($1,162.12), azathioprine ($1,193.71), chloroquine ($2,525.01), dapsone ($2750.68), cyclosporine ($2,976.32), thalidomide ($75,831.44), and lenalidomide ($316,104.03). Conclusions For medications used for CLE patients, the medication cost contributes the most to differences between direct costs. Limitations include insufficient patient outcome data to ascertain medication efficacy, exclusion of cost of medication-related adverse events and hospitalizations, and medication cost data not reflecting all payers. Clinicians can use this data to help discern which medication to prescribe CLE patients with financial constraints and reduce healthcare spending.Keywords
This publication has 4 references indexed in Scilit:
- Cost-Related Nonadherence and Mortality in Patients With Chronic Disease: A Multiyear Investigation, National Health Interview Survey, 2000–2014Preventing Chronic Disease, 2020
- Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current EraJournal of the American Society of Nephrology, 2019
- Cutaneous lupus erythematosus: Diagnosis and treatmentBest Practice & Research Clinical Rheumatology, 2013
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritisArthritis Care & Research, 2008